Ratings
0
Nobody has rated this yet. Be the first!
Works
16
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development
Apalutamide for the treatment of prostate cancer
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.
